Concise Prescribing Info
Herpes labialis.
Dosage/Direction for Use
Adult : Topical/Cutaneous As 1% cream: Appy 2 hrly during waking hr for 4 days.
Dosage Details
Recurrent herpes simplex labialis
Adult: As 1% cream: Appy 2 hrly during waking hr (approx 8 times daily) for 4 days. Initiate treatment at earliest sign or symptom.
Child: >12 yr Same as adult dose.
Hypersensitivity to penciclovir, famciclovir.
Special Precautions
Immunocompromised patients (e.g. AIDS patients, bone marrow transplant recipients). Not recommended for application to mucous membranes (e.g. eyes, mouth, nose, genitals). Pregnancy and lactation.
Adverse Reactions
Headache, taste perversion, application site reactions (e.g. stinging, burning, numbness), pruritus, pain, rash, allergic reactions, contact dermatitis.
Monitor reduction in virus shedding, negative cultures for herpes virus; resolution of pain and healing of cold sore lesion.
Description: Penciclovir has in vitro and in vivo inhibitory activity against various Herpesviridae, including herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), and EpsteinBarr virus (EBV). In cells infected w/ HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form which, in turn, is converted to penciclovir triphosphate by cellular kinases. Penciclovir triphosphate inhibits HSV polymerase competitively w/ deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited.
Absorption: Not absorbed appreciably into systemic circulation following topical administration at single or multiple doses up to a total of 180 mg (approx 67 times the proposed daily clinical dose).
Chemical Structure

Click on icon to see table/diagram/image
Store between 20-25°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Penciclovir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in